In Vitro Evaluation of Reversible and Irreversible Cytochrome P450 Inhibition: Current Status on Methodologies and their Utility for Predicting Drug–Drug Interactions

被引:4
作者
Stephen Fowler
Hongjian Zhang
机构
[1] F. Hoffmann La-Roche Ltd.,Drug Metabolism and Pharmacokinetics
[2] Bristol-Myers Squibb Research and Development,Drug Metabolism and Pharmacokinetics
来源
The AAPS Journal | 2008年 / 10卷
关键词
cytochrome P450 (CYP); drug interactions; time dependent inhibition;
D O I
暂无
中图分类号
学科分类号
摘要
It is widely accepted that today’s practice of polypharmacy inevitably increases the incidence of drug–drug interactions (DDIs). Serious DDI is a major liability for any new chemical entity (NCE) entering the pharmaceutical market. As such, pharmaceutical companies employ various strategies to avoid problematic compounds for clinical development. A key cause for DDIs is the inhibition of cytochrome P450 enzymes (CYPs) that are responsible for metabolic clearance of many drugs. Screening for inhibition potency of CYPs by NCEs has therefore become a routine practice during the drug discovery stage. However, in order to make proper use of DDI data, an understanding of the strengths and weaknesses of the various experimental systems in current use is required. An illustrated review of experimental practices is presented with discussion of likely future developments. The combination of high quality in vitro data generation and the application of in vivo CYP inhibition modelling approaches should allow more informed decisions to be made in the search for drug molecules with acceptable DDI characteristics.
引用
收藏
页码:410 / 424
页数:14
相关论文
共 204 条
[21]  
Obach R. S.(2002) activities of cDNA-expressed human cytochromes P-450 J. Biomol. Screen 7 373-382
[22]  
Weaver R.(2000)Effect of commonly used organic solvents on the kinetics of cytochrome P450 2B6- and 2C8-dependent activity in human liver microsomes Drug Metab. Dispos 28 125-130
[23]  
Graham K. S.(2002)The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties Xenobiotica 32 863-878
[24]  
Beattie I. G.(2005)Binding of drugs to hepatic microsomes: Comment and assessment of current prediction methodology with recommendation for improvement (1) Clin. Pharmacokinet 44 279-304
[25]  
Riley R. J.(2007)Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS Current Drug Metabolism 8 407-447
[26]  
Dierks E. A.(2003)Optimizing higher throughput methods to assess drug–drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 Arch. Biochem. Biophys 409 59-71
[27]  
Stams K. R.(2007) using a single point IC(50) Drug Metab. Dispos 35 246-255
[28]  
Lim H. K.(2007)Drug interactions with calcium channel blockers: Possible involvement of metabolite-intermediate complexation with CYP3A Drug Metab. Dispos 35 2159-2165
[29]  
Cornelius G.(2006)Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites Current Drug Metabolism 7 315-334
[30]  
Zhang H.(2005)Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs Drug Metab. Dispos 33 413-418